Effect of membrane permeability on survival of hemodialysis patients.

The effect of high-flux hemodialysis membranes on patient survival has not been unequivocally determined. In this prospective, randomized clinical trial, we enrolled 738 incident hemodialysis patients, stratified them by serum albumin < or = 4 and >4 g/dl, and assigned them to either low-flux or high-flux membranes. We followed patients for 3 to 7.5 yr. Kaplan-Meier survival analysis showed no significant difference between high-flux and low-flux membranes, and a Cox proportional hazards model concurred. Patients with serum albumin < or = 4 g/dl had significantly higher survival rates in the high-flux group compared with the low-flux group (P = 0.032). In addition, a secondary analysis revealed that high-flux membranes may significantly improve survival of patients with diabetes. Among those with serum albumin < or = 4 g/dl, slightly different effects among patients with and without diabetes suggested a potential interaction between diabetes status and low serum albumin in the reduction of risk conferred by high-flux membranes. In summary, we did not detect a significant survival benefit with either high-flux or low-flux membranes in the population overall, but the use of high-flux membranes conferred a significant survival benefit among patients with serum albumin < or = 4 g/dl. The apparent survival benefit among patients who have diabetes and are treated with high-flux membranes requires confirmation given the post hoc nature of our analysis.

[1]  C. Wanner,et al.  Section IV. Dialysis fluid purity. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  P. Stenvinkel,et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.

[3]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[4]  Johanna T Dwyer,et al.  Effect of dialysis dose and membrane flux in maintenance hemodialysis. , 2002, The New England journal of medicine.

[5]  J. Hornberger,et al.  A multivariate analysis of mortality and hospital admissions with high-flux dialysis. , 1992, Journal of the American Society of Nephrology : JASN.

[6]  F. Port,et al.  Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. , 2002, Kidney international.

[7]  Gerald Beck,et al.  Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. , 2003, Journal of the American Society of Nephrology : JASN.

[8]  R. Wolfe,et al.  Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the usrds dialysis morbidity and mortality study. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  R. Wolfe,et al.  Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2003, Journal of the American Society of Nephrology : JASN.

[10]  F. Port,et al.  International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. , 2006, Journal of the American Society of Nephrology : JASN.

[11]  H. Mischak,et al.  Proteomics: a novel tool to unravel the patho-physiology of uraemia. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  G. Eknoyan,et al.  Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[13]  W. März,et al.  Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  R. Vanholder,et al.  Biochemical and clinical evidence for uremic toxicity. , 2004, Artificial organs.

[15]  William Clark,et al.  Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. , 2006, Journal of the American Society of Nephrology : JASN.

[16]  R. Wolfe,et al.  Relationship of dialysis membrane and cause-specific mortality. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  B. Stengel,et al.  Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). , 2005, Kidney international.

[18]  E G Lowrie,et al.  The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. , 1993, The New England journal of medicine.

[19]  F Locatelli,et al.  The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. , 1999, Journal of nephrology.

[20]  M. Saul,et al.  A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. , 2000, The American journal of medicine.

[21]  X. Leverve,et al.  Dialyzer membrane permeability and survival in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  G. Beck,et al.  Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  C. Ronco,et al.  Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. , 1996, Kidney international.

[24]  J. Daugirdas Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. , 1993, Journal of the American Society of Nephrology : JASN.